The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV

AIDS

Volumn 26, Issue 18, 2012, Pages 2337-2344

  Cordery, Damien V ^a   Martin, Allison ^a   Amin, Janaki ^a   Kelleher, Anthony D ^a,b   Emery, Sean ^a   Cooper, David A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

Author keywords

antiretroviral therapy; body composition; HIV; lipodystrophy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HLA A01 ANTIGEN; HLA ANTIGEN; HLA B08 ANTIGEN; HLA DQ2 ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENINE; ANTI-HIV AGENTS; AUSTRALIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HLA ANTIGENS; HLA-A1 ANTIGEN; HLA-B8 ANTIGEN; HLA-DQ ANTIGENS; HUMANS; LAMIVUDINE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; ORGANOPHOSPHONATES; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYMIDINE;

EID: 84870253667     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ab213     Document Type: Article

References (29)

1. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008;8:607-618.
2. Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev 2009;22:370-385.
3. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and BM35-CwM04 disadvantage. Science 1999;283:1748-1752.
4. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA BM5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000;97:2709-2714. (Pubitemid 30159236)
5. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic Tlymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217. (Pubitemid 27064707)
6. Mackelprang RD, John-Stewart G, Carrington M, Richardson B, Rowland-Jones S, Gao X, et al. Maternal HLA homozygosity and mother-child HLA concordance increase the risk of vertical transmission of HIV-1. J Infect Dis 2008;197:1156-1161. (Pubitemid 351590051)
7. Mackelprang RD, Carrington M, John-Stewart G, Lohman-Payne B, Richardson BA, Wamalwa D, et al. Maternal human leukocyte antigen AM2301 is associated with increased mothertochild HIV-1 transmission. J Infect Dis 2010;202:1273-1277.
8. Song W, He D, Brill I, Malhotra R, Mulenga J, Allen S, et al. Disparate associations of HLA class I markers with HIV-1 acquisition and control of viremia in an African population. PLoS One 2011;6:e23469.
9. Tang J, Shao W, Yoo YJ, Brill I, Mulenga J, Allen S, et al. Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples. J Immunol 2008;181:2626-2635.
10. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-BM5701; HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-732. (Pubitemid 34215071)
11. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-BM5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-579.
12. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, et al. HLA-BM3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009;19:139-146.
13. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1M0101 and abrogated by low CD4 T-cell counts. AIDS 2005;19:97-99. (Pubitemid 40111026)
14. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726-735. (Pubitemid 36293626)
15. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-139. (Pubitemid 32150958)
16. Lake JE, Wohl D, Scherzer R, Grunfeld C, Tien PC, Sidney S, et al. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care 2011;23:929-938.
17. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, Kiertiburanakul S, Charoenyingwattana A, Komindr S, et al. Association between HLA-BM4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudinecontaining antiretroviral regimen. Clin Infect Dis 2010;50:597-604.
18. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009;49:1591-1601.
19. Martin A, Amin J, Emery S, Baker D, Carr A, Cooper DA, et al. Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One 2011;6:e26885.
20. Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010;24:2657-2663.
21. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008;9:1.
22. Doytchinova IA, Flower DR. In silico identification of supertypes for class II MHCs. J Immunol 2005;174:7085-7095. (Pubitemid 40705674)
23. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001;344:1668-1675. (Pubitemid 32479964)
24. Gao X, O'Brien TR, Welzel TM, Marti D, Qi Y, Goedert JJ, et al. HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection. AIDS 2010;24:1835-1840.
25. Naruto T, Gatanaga H, Nelson G, Sakai K, Carrington M, Oka S, et al. HLA class I mediated control of HIV-1 in Japanese, where the protective HLA-BM57 and-BM27 are absent. J Virol 2012;86:10870-10872.
26. Lazaryan A, Lobashevsky E, Mulenga J, Karita E, Allen S, Tang J, et al. Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans. J Virol 2006;80:6056-6060. (Pubitemid 43849183)
27. Dawkins R, Leelayuwat C, Gaudieri S, Tay G, Hui J, Cattley S, et al. Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease. Immunol Rev 1999;167:275-304. (Pubitemid 29178988)
28. Kaslow RA, Duquesnoy R, Van Raden M, Kingsley L, Marrari M, Friedman H, et al. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet 1990;335:927-930. (Pubitemid 20134966)
29. Flores-Villanueva PO, Hendel H, Caillat-Zucman S, Rappaport J, Burgos-Tiburcio A, Bertin-Maghit S, et al. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J Immunol 2003;170:1925-1929. (Pubitemid 36197411)